| David Rose, DO | |
|
20900 Biscayne Blvd, Aventura, FL 33180 | |
| (305) 682-7000 | |
| Not Available |
| Full Name | David Rose |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | 20900 Biscayne Blvd, Aventura, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922305341 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | OS14774 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jackson Health System | Miami, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duval Emergency Group Llc | 5991846370 | 20 |
News Archive
University of Alberta researchers have identified a unique biological marker that can be used to identify the presence of the rare autoimmune disease myasthenia gravis, predict the course of the disease and identify new, personalized treatments.
Catalyst Health Solutions, Inc. (NASDAQ:CHSI) announced today that it was named to the Fortune 100 Fastest-Growing Companies list, making its second consecutive appearance on the annual ranking and third within the past five years. Catalyst ranked Number 14 on the list of fast-growing health care companies and Number 93 overall among all industries.
Age-adjusted death rates in the United States dropped significantly between 2005 and 2006 and life expectancy hit another record high, according to preliminary death statistics released today by CDC's National Center for Health Statistics.
In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
› Verified 3 days ago
| Entity Name | Medi Partners Of South Florida, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922241579 PECOS PAC ID: 8628123577 Enrollment ID: O20090828000619 |
News Archive
University of Alberta researchers have identified a unique biological marker that can be used to identify the presence of the rare autoimmune disease myasthenia gravis, predict the course of the disease and identify new, personalized treatments.
Catalyst Health Solutions, Inc. (NASDAQ:CHSI) announced today that it was named to the Fortune 100 Fastest-Growing Companies list, making its second consecutive appearance on the annual ranking and third within the past five years. Catalyst ranked Number 14 on the list of fast-growing health care companies and Number 93 overall among all industries.
Age-adjusted death rates in the United States dropped significantly between 2005 and 2006 and life expectancy hit another record high, according to preliminary death statistics released today by CDC's National Center for Health Statistics.
In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
› Verified 3 days ago
| Entity Name | Duval Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053645465 PECOS PAC ID: 5991846370 Enrollment ID: O20100107000235 |
News Archive
University of Alberta researchers have identified a unique biological marker that can be used to identify the presence of the rare autoimmune disease myasthenia gravis, predict the course of the disease and identify new, personalized treatments.
Catalyst Health Solutions, Inc. (NASDAQ:CHSI) announced today that it was named to the Fortune 100 Fastest-Growing Companies list, making its second consecutive appearance on the annual ranking and third within the past five years. Catalyst ranked Number 14 on the list of fast-growing health care companies and Number 93 overall among all industries.
Age-adjusted death rates in the United States dropped significantly between 2005 and 2006 and life expectancy hit another record high, according to preliminary death statistics released today by CDC's National Center for Health Statistics.
In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
› Verified 3 days ago
| Entity Name | Florida Observation Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689267007 PECOS PAC ID: 9335548478 Enrollment ID: O20210524000536 |
News Archive
University of Alberta researchers have identified a unique biological marker that can be used to identify the presence of the rare autoimmune disease myasthenia gravis, predict the course of the disease and identify new, personalized treatments.
Catalyst Health Solutions, Inc. (NASDAQ:CHSI) announced today that it was named to the Fortune 100 Fastest-Growing Companies list, making its second consecutive appearance on the annual ranking and third within the past five years. Catalyst ranked Number 14 on the list of fast-growing health care companies and Number 93 overall among all industries.
Age-adjusted death rates in the United States dropped significantly between 2005 and 2006 and life expectancy hit another record high, according to preliminary death statistics released today by CDC's National Center for Health Statistics.
In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Rose, DO 20900 Biscayne Blvd, Miami, FL 33180-1495 Ph: (305) 682-7292 | David Rose, DO 20900 Biscayne Blvd, Aventura, FL 33180 Ph: (305) 682-7000 |
News Archive
University of Alberta researchers have identified a unique biological marker that can be used to identify the presence of the rare autoimmune disease myasthenia gravis, predict the course of the disease and identify new, personalized treatments.
Catalyst Health Solutions, Inc. (NASDAQ:CHSI) announced today that it was named to the Fortune 100 Fastest-Growing Companies list, making its second consecutive appearance on the annual ranking and third within the past five years. Catalyst ranked Number 14 on the list of fast-growing health care companies and Number 93 overall among all industries.
Age-adjusted death rates in the United States dropped significantly between 2005 and 2006 and life expectancy hit another record high, according to preliminary death statistics released today by CDC's National Center for Health Statistics.
In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
› Verified 3 days ago
Christopher N Hanner, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2000 Island Blvd, #1605, Aventura, FL 33160 Phone: 305-725-2447 | |
Shuai Zhao, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 20900 Biscayne Blvd, Aventura, FL 33180 Phone: -- | |
Jaskirat Gill, M.D Emergency Medicine Medicare: Medicare Enrolled Practice Location: 20900 Biscayne Blvd, Aventura, FL 33180 Phone: 305-692-3392 | |
Jennifer Ashley Reyes, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 20900 Biscayne Blvd, Aventura, FL 33180 Phone: 512-636-5737 | |
Dr. Foluso Akinradewo, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 20900 Biscayne Blvd, Gme South Tower Room 821, Aventura, FL 33180 Phone: 305-692-3392 | |
Dr. Eva Ryder, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 20900 Biscayne Blvd, Aventura, FL 33180 Phone: 305-682-7000 | |
Trung Tran, MD, MPH Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 20900 Biscayne Blvd, Aventura, FL 33180 Phone: 305-692-3392 |